Servier and MiNA Target Neurodegenerative Disease With Novel RNA Therapy
$267m Deal Expands Biotech’s Research
Already partnering with AZ and Boehringer Ingelheim in liver targets, the UK biotech sees potential to hit ‘undruggable’ CNS targets as well.
You may also be interested in...
Advances in small activating RNAs, pioneered by MiNA Therapeutics, have caught the eye of Eli Lilly, and could be the next platform to exploit gene control mechanisms to produce a new therapeutic modality.
After the Aduhelm controversy, Biogen has another neurodegenerative disease drug which so far can only show efficacy against surrogate biomarkers – will the FDA be swayed again this time?
Having finally confirmed the Sandoz spin-off, Novartis will become a 'pure play' pharma company and focus on picking bigger blockbuster winners from both internal and external pipelines. CEO Vas Narasimhan talked details at an investor day in Basel.